Studies show patients with chronic kidney disease (CKD) and COVID-19 are at increased risk for an intensive care unit stay and early death. Anemia is an extra risk factor.

Peter L. Salgo, MD: We’ve been talking around all of this in terms of therapeutic options and transfusions, and I know we’re going to get down in the weeds on this in a little bit. This might be a ...

daily multivitamin does not reduce the risks of cvd in men Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be ...

Anemia is a common complication of stages 3b to 5 CKD. Patients with CKD aren’t always compliant with taking supplemental oral iron, as recommended for the treatment of comorbid anemia. Inflammation ...

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

Chronic kidney disease (CKD) is a slow health problem that affects how well your kidneys clean your blood. It has five stages ...

Credit: Getty Images. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the treatment of ...

Chronic kidney disease or CKD, is a condition that builds over time, as a result of inappropriate kidney function. The ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic kidney disease and their care partners report a considerable burden, especially when the ...

Daprodustat offers anemia of chronic kidney disease patients a more convenient treatment than the current standard of care. The drug could generate $1 billion in annual sales for the company. The ...